Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A | Experimental |
| |
| B | Experimental |
| |
| C | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gabapentin | Drug | Gabapentin 100 mg oral capsule 30 minutes prior to bedtime |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Subjective sleep latency | Hour +8 |
| Measure | Description | Time Frame |
|---|---|---|
| Stanford Sleepiness Scale | Hour +13 | |
| Vital signs | Hour +8 | |
| Adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | San Diego | California | 92108 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Gabapentin |
| Drug |
Gabapentin 250 mg oral capsule 30 minutes prior to bedtime |
|
| Placebo | Drug | Matched placebo 30 minutes prior to bedtime |
|
| Hour +13 |
| Subjective number of awakenings | Hour +8 |
| Subjective wake after sleep onset | Hour +8 |
| Subjective total sleep time | Hour +8 |
| Subjective assessment of sleep refreshment | Hour +8 |
| Subjective assessment of sleep quality | Hour +8 |
| Karolinska Sleep Diary-Sleep (KSD) Quality Index | Hour +8 |
| KSD individual scores | Hour +8 |
| Digit Symbol Substitution Test | Hour +8 |
| Buschke Selective Reminding Test (immediate recall score, long term storage score, total number of intrusions, delayed recall score) | Hour +8 |
| Ocala |
| Florida |
| 34471 |
| United States |
| Pfizer Investigational Site | Atlanta | Georgia | 30328 | United States |
| Pfizer Investigational Site | Atlanta | Georgia | 30342 | United States |
| Pfizer Investigational Site | Metairie | Louisiana | 70001 | United States |
| Pfizer Investigational Site | New York | New York | 10025 | United States |
| Pfizer Investigational Site | Thornwood | New York | 10594 | United States |
| Pfizer Investigational Site | Raleigh | North Carolina | 27612 | United States |
| Pfizer Investigational Site | Duncansville | Pennsylvania | 16635 | United States |
| Pfizer Investigational Site | Johnstown | Pennsylvania | 15904 | United States |
| ID | Term |
|---|---|
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077206 | Gabapentin |
| ID | Term |
|---|---|
| D000588 | Amines |
| D009930 | Organic Chemicals |
| D005680 | gamma-Aminobutyric Acid |
| D000613 | Aminobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D003509 | Cyclohexanecarboxylic Acids |
| D000146 | Acids, Carbocyclic |
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D000596 | Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
Not provided
Not provided